What is Notch Therapeutics?
Based in Vancouver, Canada, Notch Therapeutics operates at the intersection of synthetic biology and oncology. The company specializes in the development of renewable, induced pluripotent stem cell-derived cell therapies. By leveraging a sophisticated platform designed to engineer immune cells, Notch aims to overcome the traditional limitations associated with autologous cell therapies, such as manufacturing complexity and patient accessibility. Their approach is fundamentally transformative, seeking to provide off-the-shelf solutions that can be deployed more efficiently within clinical settings to treat a variety of hematologic malignancies and solid tumors.
How much funding has Notch Therapeutics raised?
Notch Therapeutics has raised a total of $85M across 1 funding round:
Series A
$85M
Series A (2021): $85M with participation from CCRM Enterprises Holdings, Lumira Ventures, and Allogene Therapeutics
Key Investors in Notch Therapeutics
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, from early-stage to revenue-generating biotech, biotherapeutics, and medical devices.
CCRM Enterprises Holdings
CCRM Enterprises Holdings acts as the commercialization arm of the Centre for Commercialization of Regenerative Medicine, focusing on bridging the gap between academic research and industrial application in the regenerative medicine sector.
Allogene Therapeutics
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T cell therapies for cancer, providing strategic industry expertise and collaborative support.
What's next for Notch Therapeutics?
With this major strategic investment, Notch Therapeutics is expected to focus on scaling its manufacturing capabilities and expanding its clinical trial infrastructure. The company's roadmap involves transitioning its lead programs from preclinical validation to human clinical studies, a phase that requires substantial operational resources and specialized expertise. Furthermore, the firm will likely continue to cultivate strategic partnerships with established biopharmaceutical entities to enhance its commercialization strategy. As the company matures, the focus will shift toward demonstrating the safety and efficacy of its engineered cell products, ultimately aiming to redefine the standard of care for patients battling complex cancers.
See full Notch Therapeutics company page
